Sunbird Bio is a biotechnology company developing proprietary blood-based diagnostic tests that provide unprecedented insights to enable earlier, more accurate diagnosis and treatment of neurological disorders and early-stage cancer. Sunbird's innovative technologies uniquely detect the property and activity of proteins to empower researchers and clinicians with actionable information that is not available or accessible from current tests. Sunbird Bio's unparalleled leadership in blood-based diagnostics positions the company to become a global leader in the field, addressing significant research and clinical gaps, and serving multiple, sizable markets.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
10/16/24 | $14,000,000 |
ClavystBio EDBI Eli Lilly and Company Polaris Partners S32 | undisclosed |